Porton Pharma Solutions Ltd.

Porton Advanced provides end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs), from cell banking, process and analyticals method development, cGMP production to fill&finish, covering different stages of drug development from early research, investigator-initiated trials, Investigat...

Porton Biologics and Conjugates CDMO Platform delivers one-stop drug development solution. Our expertise covers diverse modalities like ADCs, AOCs, PDCs, and RDCs.
Our core strength lies in a team of 150+ scientists. They've successfully managed 50+ projects from IND to NDA stages, serving 40+ g...

Porton Pharma is a global CDMO leader in small molecule APIs, offering efficient, flexible solutions throughout drug development—from pre-clinical to commercial production—for partners worldwide. With infrastructure exceeding 2200 m³, we support both early innovation and large-scale manufacturing....

Our platform integrates 4 R&D powerhouses: peptides, oligonucleotides and drug delivery materials, to offer end-to-end CMC solutions. From pre-clinical to commercial triumphs, we empower global clients with unparalleled expertise.
With a team of over 150 scientists, we won a robust track r...

As a global CDMO serving global innovative pharmaceutical companies and research institutions, Porton has an extensive experience in research and manufacturing services, especially in the field of PROTAC drug development. Porton is committed to the development and production of PROTAC oral formulations and provides customers with comprehensive, reliable, fast, and compliant one-stop services, to meet customers' supply chain needs and facilitating the commercial success of their products from research and development to order fulfillment.

Continuous reaction can effectively solve the problem of "amplification effect" in batch processes from research and development to pilot testing, and then again to commercial production. Porton’s continuous reaction capabilities include low-temperature lithiation reaction, ozone oxidation reaction, nitrification reaction, high-temperature reaction, and organic azide reaction, etc., which can achieve process development and technology transfer from research and development to production application. 

This white paper details our extensive capabilities in Analytical Research and Development (R&D) and Quality Control (QC) for pharmaceutical drug development. It highlights our expertise in method development, structure elucidation, and method troubling.  Our goal is to ensure the highest standards of quality and efficiency in drug development and manufacturing.

Antibody drug conjugates (ADCs) have seen significant breakthroughs and reached numerous milestones since 2000 when the first ADC was approved by the FDA and have shown great promise for the treatment of cancer. First generation ADCs were designed to use the affinity of an antibody towards a specific cellular target to bring the cytotoxic payload to the tumor, for example. However, some level of off-target toxicity was often seen with many ADCs because other cellular interactions could occur prior to the payload physically reaching its intended target or the payload could cleave off. These events could lead to unintended death of non-cancerous cells.

Drug discovery is an exceedingly complex process. Discovering a new chemical entity is in itself a huge accomplishment, which is often possible only after almost two decades of hard experimental work as well as advanced simulation efforts. Therefore, the next stage of the process, determination of toxicity becomes even more crucial as most new chemical entities (NCE) are disqualified if the NCE shows a potential toxic effect, despite any possible therapeutic effect.

The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.

Antibody Drug Conjugate (ADC) CDMO Services As a subsidiary of the globally recognized CDMO——Porton Pharma Solutions, Porton Biologics CDMO Platform is designed to provide one-stop drug development and manufacturing services for antibodies and antibody drug conjugates (ADCs).

With four major R&D platforms including peptides, oligonucleotides, high-performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.

Porton Pharma Solutions is a top global CDMO. It has advanced manufacturing facilities in the US, EU, and China, all following strict R&D and GMP standards. The company provides innovative, reliable, and customer-focused CDMO solutions for various products, including small molecules, tides, biologics, conjugates (such as ADCs, AOCs, PDCs, RDCs), and advanced therapy medicinal products, covering all stages from preclinical research to commercial production.

With 18 sites worldwide, Porton offers quick client support. It has over 4,200 employees, including more than 1,200 R&D and technical experts, driving innovation and maintaining high operational standards. Its production capacity is about 2,200 m³, meeting different needs. Having served over 1,200 global clients and handled over 4,000 milestone projects, Porton demonstrates strong business sense and an excellent reputation. In 2024, it achieved $424 million in revenue.

✔️ Comprehensive Support: We cover every stage of hashtag#PROTAC drug development.
✔️ Global Standards: Adhering strictly to international norms ensures quality and reliability.
✔️ Problem Solvers: Tackling drug development issues.

1. Process Design, Route Scouting, Development and Optimization for APIs and Intermediates2. non-GMP and GMP Manufacturing for APIs and Intermediates, pre-clinical to Commercial
3. Pre-formulation Research and Process Development & Optimization
4. GMP Manufacturing for Drug Products, from Pre-clinical to Commercial Batches
5. Comprehensive Analytical R&D and Quality Control 
6. IND/NDA Dossier and CMC Solutions

Founded in 2022, Porton Pharma Tech Slovenia, the first CDMO inSlovenia's pharma sector & a European subsidiary of Porton PharmaSolutions, provides clients with services from synthesis -route development, process work, analytical methodsevaluation and validation to process scale-up.

Porton has a professional technology platform and an experierced team to provide global clientswith CMC solutions for radiopharmaceutical precursors and colodrugs. We are committed tobecoming the leading RDC CDMO company in China.

The Building Block for Conjugates(Antibody & Payload-Linker)Catalog ProductsOne Stop CDMO Services for Conjugate Products

The Building Block for Tides(Peptides & Oligonucleotides)

Porton Pharma Solutions, a global company with R&D, and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, etc.) from pre-clinical to commercial.